Business

BioRationality: A Calculated View on the Future of Biosimilars

August 21st 2023

By Sarfaraz K. Niazi, PhD

Sarfaraz K. Niazi, PhD, recapped his answers to a recent interview where he discussed his predictions on the future of the biosimilar industry in the United States.

How Streamlining Development Can Save the US Biosimilar Industry

August 20th 2023

By Skylar Jeremias

Podcast

On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, expanded on ways to make biosimilar development faster and cheaper without compromising on safety and efficacy and how these practices can ensure a sustainable market for the future.

Biocon Biosimilar Quarterly Sales Up 106%

August 17th 2023

By Skylar Jeremias

Article

In Biocon’s latest quarterly earnings report, the company revealed that sales for its biosimilars portfolio rose 106% compared with the same time frame the year prior.

STADA Earnings Project Record Breaking Profits for 2023

August 16th 2023

By Skylar Jeremias

Article

In STADA Arzneimittel’s first half of 2023 earnings report, the company disclosed double-digit growth, suggesting that it could see profits hit an all-time high by the end of the year.

Despite Global Increase in Amjevita Sales, US Sales Dropped 63%

August 5th 2023

By Skylar Jeremias

Article

Despite global sales for Amjevita (adalimumab-atto) growing by 29% year-over-year and the agent being the first adalimumab biosimilar on the US market, sales in the United States dropped 63% from the first quarter to the second quarter of 2023.

Biosimilar Business News Recap: 3 Biosimilar Application Submissions; Roche Sues Biogen

July 26th 2023

By Skylar Jeremias

Article

Formycon and Celltrion announced the FDA submissions for their aflibercept biosimilars; the European Medicines Agency accepted a marketing authorization application for an ustekinumab biosimilar; and Roche filed suit against Biogen over a tocilizumab biosimilar.

AAM White Paper Breaks Down Drug Shortage Crisis: Causes and Solutions

July 25th 2023

By Skylar Jeremias

Article

The Association for Accessible Medicines (AAM) published a white paper on the impact that ongoing drug shortages have had on the generic and biosimilar industries as well as possible solutions stakeholders can put into action.

Eye on Pharma: Omalizumab Results; Korean Insulin Launch; Quebec to Cover Byooviz

July 12th 2023

By Skylar Jeremias

Article

Kashiv Biosciences announced positive phase 1 results for its omalizumab biosimilar; Dongkook Pharmaceutical shared the launch of an insulin glargine biosimilar (Glargia); and Quebec, a province in Canada, said it’s adding a ranibizumab biosimilar (Byooviz) to its reimbursement list.

US Welcomes Idacio, Hulio to the Adalimumab Biosimilar Market

July 5th 2023

By Skylar Jeremias

Article

The US gains 2 more adalimumab biosimilars on the market: Fresenius Kabi's Idacio (adalimumab-aacf) and Biocon Biologic's Hulio (adalimumab-fkjp). The launches come after 5 launched over the Fourth of July weekend.

Biosimilars Business Roundup for June 2023—Podcast Edition

July 2nd 2023

By Justina Petrullo

Podcast

On this episode, we’re going to be recapping some of the biggest stories in the business space regarding biosimilars, including adalimumab preparation, partnerships for commercialization, and more.